Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review.
Corrado CampochiaroMaria Grazia LazzaroniCosimo BruniElisabetta ZanattaGiacomo De LucaMarco Matucci CerinicPublished in: Therapeutic advances in musculoskeletal disease (2022)
Our SLR supports the use of RTX, TCZ and nintedanib for SSc-ILD patients and underlines the need for more data about upfront combination versus monotherapy. It also highlighted the need to identify predictors supporting drug choice according to both pulmonary and extra-pulmonary manifestations.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- idiopathic pulmonary fibrosis
- rheumatoid arthritis
- end stage renal disease
- pulmonary hypertension
- newly diagnosed
- ejection fraction
- chronic kidney disease
- electronic health record
- peritoneal dialysis
- combination therapy
- prognostic factors
- minimally invasive
- randomized controlled trial
- open label
- drug induced
- emergency department
- clinical trial
- patient reported outcomes
- adverse drug
- data analysis
- deep learning